Get the Stockscreener App
2.85
3.39%
-0.10
Pre-market:
2.83
-0.02
-0.70%
Esperion Therapeutics Inc stock is traded at $2.85, with a volume of 5.57M.
It is down -3.39% in the last 24 hours and down -13.64% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.95
Open:
$2.9
24h Volume:
5.57M
Relative Volume:
0.84
Market Cap:
$574.63M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3443
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-6.25%
1M Performance:
-13.64%
6M Performance:
+161.47%
1Y Performance:
+42.50%
1-Day Range:
$2.80
$2.97
1-Week Range:
$2.78
$3.04
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.85 | 683.29M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Appoints New Chief Commercial Officer - TipRanks
Esperion appoints John Harlow as chief commercial officer - Investing.com
Esperion Therapeutics Appoints New Chief Commercial Officer - TradingView
Esperion Appoints John Harlow as Chief Commercial Officer to Drive Growth and Innovation - Quiver Quantitative
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer - The Manila Times
Esperion (NASDAQ: ESPR) appoints John Harlow CCO; led 85% revenue growth at Melinta - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Relative strength of Esperion Therapeutics Inc. in sector analysisPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionBuy Signal & Safe Capital Investment Plans - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fakeJuly 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price target2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.July 2025 Update & Safe Entry Point Alerts - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.July 2025 Intraday Action & Community Consensus Trade Alerts - newser.com
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Top Gainers & Technical Pattern Based Signals - newser.com
Will Esperion Therapeutics Inc. stock return to pre crisis levelsQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using AI based signals to follow Esperion Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Stock Forecasts - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersJuly 2025 Action & Daily Volume Surge Signals - newser.com
Esperion to Participate in Jefferies Global Healthcare ConferenceLondon - The Manila Times
Esperion (NASDAQ: ESPR) to webcast Nov 18 Jefferies Global Healthcare Conference presentation - Stock Titan
Can volume confirm reversal in Esperion Therapeutics Inc.Quarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-03 04:49:46 - newser.com
Published on: 2025-11-03 03:31:08 - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Published on: 2025-11-03 01:10:01 - newser.com
Why Esperion Therapeutics Inc. is moving todayJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How high can Esperion Therapeutics Inc. stock goPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Why analysts remain bullish on Esperion Therapeutics Inc. stock2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Multi asset correlation models including Esperion Therapeutics Inc.Buy Signal & Verified Short-Term Plans - newser.com
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.60%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):